乙肝病毒基因型对拉米夫定治疗后乙肝e抗原血清学转换无影响。
Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment.
作者信息
Chan Henry Lik-Yuen, Wong May-Ling, Hui Alex Yui, Chim Angel Mei-Ling, Tse Ada Mei-Ling, Hung Lawrence Cheung-Tsui, Chan Francis Ka-Leung, Sung Joseph Jao-Yiu
机构信息
Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong.
出版信息
World J Gastroenterol. 2003 Dec;9(12):2695-7. doi: 10.3748/wjg.v9.i12.2695.
AIM
To investigate the association of hepatitis B virus (HBV) genotype and HBeAg seroconversion after nucleotide analogue treatment.
METHODS
Chronic hepatitis B patients receiving lamivudine followed up for at least 6 months post-treatment were studied. Consecutive treatment-naïve patients who were prospectively followed up in the clinic for at least 18 months were studied as controls. HBeAg seroconversion was defined as loss of HBeAg, appearance of anti-HBe and normalization of alanine aminotransferase for at least 6 months.
RESULTS
Thirty-five patients on lamivudine and 96 control patients followed up for 39 (18-49) months were studied. Lamivudine was given for 12 (10-18) months, and patients were followed up for 15 (6-34) months after drug cessation. Genotype B and C HBV were found in 43 and 88 patients and HBeAg seroconversion occurred in 12 (28%) and 16 (18%) patients, respectively (P=0.30). There was no difference in HBeAg seroconversion between patients infected by genotype B and C HBV in the control (35% vs 21%, P=0.25) and lamivudine-treated (14% vs 10%, P=1.00) groups.
CONCLUSION
HBeAg seroconversion after treatment by lamivudine was not influenced by the HBV genotype.
目的
研究核苷酸类似物治疗后乙肝病毒（HBV）基因型与HBeAg血清学转换的相关性。
方法
对接受拉米夫定治疗且治疗后随访至少6个月的慢性乙型肝炎患者进行研究。将在门诊前瞻性随访至少18个月的初治患者作为对照。HBeAg血清学转换定义为HBeAg消失、抗-HBe出现且丙氨酸转氨酶正常化至少6个月。
结果
对35例接受拉米夫定治疗的患者和96例对照患者进行了为期39（18 - 49）个月的随访研究。拉米夫定治疗时间为12（10 - 18）个月，停药后患者随访15（6 - 34）个月。43例和88例患者分别检测到B型和C型HBV，HBeAg血清学转换分别发生在12例（28%）和16例（18%）患者中（P = 0.30）。在对照组（35%对21%，P = 0.25）和拉米夫定治疗组（14%对10%，P = 1.00）中，感染B型和C型HBV的患者之间HBeAg血清学转换无差异。
结论
拉米夫定治疗后的HBeAg血清学转换不受HBV基因型的影响。
Zotero 插件